Findings showed that in patients treated with glecaprevir/pibrentasvir, the overall SVR12 rate was 96%, with 0 patients experiencing virologic failure. The Food and ...
A widely used pangenotypic combination therapy has moved closer to European approval for acute hepatitis C virus (HCV) infection, offering clinicians a new option for early-stage treatment across all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results